UPMOORE - Prof. Moore Group
10:05alpha-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9), in Neurobiology Of Disease, vol. 73, p. 229-243, 2015.
08:06Exploring new therapeutic strategies for Huntington's Disease. Thèse EPFL, n° 6322 (2014)
14:48Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration, in Neurobiology Of Disease, vol. 71, p. 345-358, 2014.
10:32Exploring the pathological interaction between LRRK2 and alpha-synuclein: two key genes implicated in Parkinson's disease. Thèse EPFL, n° 6335 (2014)
11:22Elucidating the molecular and cellular functions of ATP13A2, LRRK2 and VPS35 in the pathophysiology of Parkinson's disease. Thèse EPFL, n° 6312 (2014)
16:16LRRK2 secretion in exosomes is regulated by 14-3-3, in Human Molecular Genetics, vol. 22, num. 24, p. 4988-5000, 2013.
09:34Divergent alpha-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases, in Neurobiology Of Disease, vol. 58, p. 183-190, 2013.
14:48Defining the Protein Interactome of Parkinson's Disease-Associated LRRK2. Thèse EPFL, n° 5699 (2013)
11:26Neurodegenerative phenotypes in an A53T-synuclein transgenic mouse model are independent of LRRK2, in Human Molecular Genetics, vol. 21, p. 2420-2431, 2012.
11:24Mechanisms of LRRK2-Mediated Neurodegeneration, in Current Neurology And Neuroscience Reports, vol. 12, p. 251-260, 2012.